Global footprint Nabriva operates in the US, Ireland, and Austria with a commercial focus on antibiotics like Xenleta and Contepo, presenting sales opportunities across North America and Europe through existing distributors and potential new partnerships in markets where approvals or asset divestitures create gaps.

Asset divestitures Recent asset sales of Contepo and Xenleta rights to Meitheal and Sumitomo Pharma respectively open channels for new licensees or co-promotion deals, enabling strategic BD discussions with buyers or regional partners seeking to expand their infectious disease portfolios.

Pipeline leverage Contepo and Xenleta offer a dual-infection portfolio with potential cross-sell to hospitals and specialty distributors, suggesting bundled or tiered pricing strategies, as well as opportunity to pitch into cUTI treatment programs and perioperative infection protocols.

Regulatory momentum FDA approval of Xenleta for oral and IV use strengthens entry into hospital and outpatient settings; continued NDA activity for Contepo indicates ongoing regulatory visibility that can be timed for BD outreach to payer groups, ID clinicians, and hospital formulary committees.

Plus strategic partnerships Historical partnerships (Merck, Er-Kim Ilac) and a lean 11-50 employee base suggest scalable BD approaches through regional distributors, CRO/CMO collaborations, and managed access programs to accelerate market penetration and share leverage with larger pharma collaborators.